a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

NCT07007949 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
IDH1 Gene Mutation
Ivosidenib

Interventions

DRUG: Ivosidenib combined with venetoclax and azacitidine
DRUG: Ivosidenib combined with venetoclax and azacitidine

Sponsor

The First Affiliated Hospital of Soochow University